JP2020529862A5 - - Google Patents
Info
- Publication number
- JP2020529862A5 JP2020529862A5 JP2020520425A JP2020520425A JP2020529862A5 JP 2020529862 A5 JP2020529862 A5 JP 2020529862A5 JP 2020520425 A JP2020520425 A JP 2020520425A JP 2020520425 A JP2020520425 A JP 2020520425A JP 2020529862 A5 JP2020529862 A5 JP 2020529862A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- percentage homology
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023061568A JP7490109B2 (ja) | 2017-06-25 | 2023-04-05 | 抗ｐｄ－１抗体とその作製及び使用方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762524557P | 2017-06-25 | 2017-06-25 | |
| US201762524553P | 2017-06-25 | 2017-06-25 | |
| US201762524554P | 2017-06-25 | 2017-06-25 | |
| US201762524558P | 2017-06-25 | 2017-06-25 | |
| US62/524,553 | 2017-06-25 | ||
| US62/524,554 | 2017-06-25 | ||
| US62/524,557 | 2017-06-25 | ||
| US62/524,558 | 2017-06-25 | ||
| US201762545603P | 2017-08-15 | 2017-08-15 | |
| US62/545,603 | 2017-08-15 | ||
| PCT/US2018/039147 WO2019005635A2 (en) | 2017-06-25 | 2018-06-22 | ANTI-PD-1 ANTIBODIES AND METHODS OF PREPARATION AND USE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023061568A Division JP7490109B2 (ja) | 2017-06-25 | 2023-04-05 | 抗ｐｄ－１抗体とその作製及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020529862A JP2020529862A (ja) | 2020-10-15 |
| JP2020529862A5 true JP2020529862A5 (enExample) | 2022-01-17 |
| JP7601635B2 JP7601635B2 (ja) | 2024-12-17 |
Family
ID=64742653
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520425A Active JP7601635B2 (ja) | 2017-06-25 | 2018-06-22 | 抗ｐｄ－１抗体とその作製及び使用方法 |
| JP2023061568A Active JP7490109B2 (ja) | 2017-06-25 | 2023-04-05 | 抗ｐｄ－１抗体とその作製及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023061568A Active JP7490109B2 (ja) | 2017-06-25 | 2023-04-05 | 抗ｐｄ－１抗体とその作製及び使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11466084B2 (enExample) |
| EP (1) | EP3645740A4 (enExample) |
| JP (2) | JP7601635B2 (enExample) |
| CN (1) | CN110799537B (enExample) |
| WO (1) | WO2019005635A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6881658B2 (ja) | 2019-07-05 | 2021-06-02 | 小野薬品工業株式会社 | Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療 |
| US20220332825A1 (en) | 2019-08-08 | 2022-10-20 | Ono Pharmaceutical Co., Ltd. | Bispecific protein |
| MX2023002279A (es) * | 2020-08-27 | 2023-03-10 | Shanghai Junshi Biosciences Co Ltd | Uso de un anticuerpo anti-pd-1 en el tratamiento del carcinoma nasofaringeo. |
| TW202241957A (zh) * | 2021-02-10 | 2022-11-01 | 大陸商上海濟煜醫藥科技有限公司 | 抗ｐｄ－１抗體及其用途 |
| CN116687933B (zh) * | 2022-02-28 | 2025-10-31 | 中国科学院上海药物研究所 | 甲氨蝶呤及其药物组合物在肿瘤免疫治疗中的用途 |
| CN120813375A (zh) | 2023-01-30 | 2025-10-17 | 凯玛布有限公司 | 抗体 |
| CN119775428B (zh) * | 2024-12-12 | 2025-08-05 | 广东沃博生物医药科技有限公司 | 一种免疫细胞的制备方法及其在治疗疾病中的用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CN101899114A (zh) * | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| DK2439273T3 (da) * | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| BR122017025062B8 (pt) * | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| TW201134488A (en) * | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| AU2014309199B2 (en) * | 2013-08-20 | 2018-04-19 | Merck Sharp & Dohme Llc | Treating cancer with a combination of a PD-1 antagonist and dinaciclib |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| PE20170255A1 (es) * | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| BR112017001385B1 (pt) * | 2014-07-22 | 2023-12-05 | Cb Therapeutics, Inc. | Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão |
| HUE068868T2 (hu) * | 2015-07-30 | 2025-02-28 | Macrogenics Inc | PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások |
| ES2924402T3 (es) * | 2015-10-02 | 2022-10-06 | Symphogen As | Anticuerpos anti-PD-1 y composiciones |
-
2018
- 2018-06-22 WO PCT/US2018/039147 patent/WO2019005635A2/en not_active Ceased
- 2018-06-22 CN CN201880038220.XA patent/CN110799537B/zh active Active
- 2018-06-22 EP EP18823869.5A patent/EP3645740A4/en active Pending
- 2018-06-22 US US16/615,113 patent/US11466084B2/en active Active
- 2018-06-22 JP JP2020520425A patent/JP7601635B2/ja active Active
-
2023
- 2023-04-05 JP JP2023061568A patent/JP7490109B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020529863A5 (enExample) | ||
| JP2020529862A5 (enExample) | ||
| JP2020531043A5 (enExample) | ||
| JP7685095B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP2020530776A5 (enExample) | ||
| IL276830B2 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| JP2024037894A5 (enExample) | ||
| AU2022350588A1 (en) | Antibody, antibody-drug conjugate thereof and use thereof | |
| WO2021213434A1 (zh) | 一种抗Nectin-4的抗体及其应用 | |
| JP7399852B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP2022515318A5 (enExample) | ||
| JP2023509196A5 (enExample) | ||
| WO2017016497A1 (en) | Anti-pd-1 antibodies and uses thereof | |
| CN110869389A (zh) | 抗ror1抗体及其制备和使用方法 | |
| JP2020501531A5 (enExample) | ||
| RU2017114968A (ru) | Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171) | |
| JP2024532886A5 (enExample) | ||
| JP2021501575A5 (enExample) | ||
| CN110831972A (zh) | 抗pd-l1抗体及其制备和使用方法 | |
| EP4242231A1 (en) | Anti-siglec-15 antibody and application thereof in preparing drug | |
| CN119053607B (zh) | 喜树碱类化合物及其偶联物、其制备方法和用途 | |
| CA3147887A1 (en) | Composition and methods of targeting the pre-b cell receptor for the treatment of leukemias and lymphomas | |
| RU2024107459A (ru) | Биспецифическое тетравалентное антитело против egfr и her3 | |
| CA3232304A1 (en) | Use of anti-cd40 antibody | |
| WO2025040000A1 (zh) | 5t4抗体药物偶联物及其应用 |